Table 24, Goal Attainment Scaling Total Score at all Time Points (Except Week 4) (Dose per Leg) for Study 141 — ITT Population - Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug.

Cover of Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic)

Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet].

Show details

Contents

Table 24Goal Attainment Scaling Total Score at all Time Points (Except Week 4) (Dose per Leg) for Study 141 — ITT Population

	AboBoNTA 10 U/kg/leg (N = 79)	AboBoNTA 15 U/kg/leg (N = 79)	Placebo (N = 77)
Week 12
n (%)	▬	▬	▬
Mean change (SD)	▬	▬	▬
LS mean change (95% CI)	▬	▬	▬
LS mean change vs. placebo (95% CI)	▬	▬	▬
P value	▬	▬	▬
Week 16
n (%)	▬	▬	▬
Mean change (SD)	▬	▬	▬
LS mean change (95% CI)	▬	▬	▬
LS mean change vs. placebo (95% CI)	▬	▬	▬
Week 22
n (%)	▬	▬	▬
Mean change (SD)	▬	▬	▬
LS mean change (95% CI)	▬	▬	▬
LS mean change vs. placebo (95% CI)	▬	▬	▬
Week 28^a
n (%)	▬	▬	▬
Mean change (SD)	▬	▬	▬

: aboBoNTA = abobotulinumtoxinA; ANOVA = analysis of variance; BoNT = botulinum toxin; Cl = confidence interval; ITT = intention-to-treat; LS = least squares; N = number of patients in group; n = number of patients with data; SD = standard deviation; U = unit; vs. = versus.
: ▬▬▬▬▬
: ▬▬▬▬▬
: Source: Study 141 Clinical Study Report.²²

From: Appendix 4, Detailed Outcome Data

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

Cite this Page
Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Aug. Table 24, Goal Attainment Scaling Total Score at all Time Points (Except Week 4) (Dose per Leg) for Study 141 — ITT Population.
PDF version of this title (962K)

Other titles in this collection

CADTH Common Drug Reviews

Recent Activity

Clear Turn Off Turn On

Table 24, Goal Attainment Scaling Total Score at all Time Points (Except Week 4)...
Table 24, Goal Attainment Scaling Total Score at all Time Points (Except Week 4) (Dose per Leg) for Study 141 — ITT Population - Clinical Review Report: abobotulinumtoxinA (Dysport Therapeutic)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on